Aficamten for symptoms in non-obstructive hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study tests a medication called aficamten in people with non-obstructive hypertrophic cardiomyopathy (a thickened heart muscle that affects how well the heart works). The goal is to see if it improves symptoms like fatigue and shortness of breath and helps you feel better in daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You need a confirmed diagnosis of hypertrophic cardiomyopathy (a condition where the heart muscle is thicker than normal).
- You must have symptoms like fatigue, shortness of breath, chest pain, palpitations, or fainting, and your heart's outflow tract gradient (a measure of blockage) should be below 30 mmHg.
- Your heart's pumping function (ejection fraction) must be 60% or above.
- You cannot be pregnant or planning to become pregnant during the trial, and you cannot be in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
This study follows people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, to learn more about how it affects them in real life. It may help doctors better understand and manage the condition.
This trial tests whether a personalized exercise program can safely improve fitness and daily activity for people with hypertrophic cardiomyopathy (a heart muscle condition). You would work with experts to build a routine that fits your needs and current health.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.